Skip to main content
PLSE
NASDAQ Industrial Applications And Services

CEO and Co-Chairman Signal Intent to Purchase Shares via Existing ATM Program

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$18.64
Mkt Cap
$1.272B
52W Low
$12.56
52W High
$26.3
52W Position info
48% above low
Off High info
29% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PLSE sits 48% above its 52-week low of $12.56.

Summary

Pulse Biosciences announced that its Board approved affiliates to purchase shares through its existing ATM program, with the CEO and Co-Chairman indicating they are likely to buy shares in the near term.


Key Events · Financing and Capital Events · PLSE

  • Board Approves Affiliate Purchases via ATM

    The Board of Directors approved resolutions permitting affiliates to purchase common stock through the existing Equity Distribution Agreement (ATM program) established on February 19, 2026, without a discount to the market price.

  • CEO and Co-Chairman Indicate Intent to Buy

    Mr. Robert Duggan, Co-Chairman and 72% beneficial owner, and Mr. Paul LaViolette, CEO and Co-Chairman, have indicated they are likely to purchase shares in the near term, though no binding commitments or specific amounts have been disclosed.

  • Reinforces Confidence Post-Clinical Data

    This potential insider buying follows recent highly positive 12-month clinical data for the nPulse Cardiac Catheter System, reinforcing investor confidence in the company's strategic direction and product pipeline.


Analysis · PLSE · Industrial Applications And Services

This filing signals a strong vote of confidence from Pulse Biosciences' top leadership and largest shareholder. The Board's approval for affiliates to purchase shares through the existing At-The-Market (ATM) program, coupled with the explicit indication from the CEO and Co-Chairman (who also beneficially owns 72% of outstanding stock) that they are likely to buy, is a significant positive development. While the ATM program itself allows for dilution, direct insider purchases through this mechanism provide capital to the company and demonstrate conviction in its future, especially following recent positive clinical data for its nPulse Cardiac Catheter System. Investors should monitor subsequent Form 4 filings for actual purchase activity.

At the time of this filing, PLSE was trading at $18.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLSE - Latest Insights

PLSE
Aug 06, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $42.27 info
Change: +$3.87 (+10%) info
Market Cap: $3.025B info
PLSE
Aug 06, 2026, 5:04 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $42.27 info
Change: +$3.87 (+10%) info
Market Cap: $3.025B info
PLSE
Aug 06, 2026, 4:21 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $36.23
Real-time Price: $42.27 info
Change: +$6.04 (+17%) info
Market Cap: $3.025B info
PLSE
Aug 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.23
Real-time Price: $42.27 info
Change: +$6.04 (+17%) info
Market Cap: $3.025B info
PLSE
Jul 29, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.35
Real-time Price: $42.27 info
Change: +$6.92 (+20%) info
Market Cap: $3.025B info